Annual Report 2020

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2020 79 The United Laboratories International Holdings Limited Annual Report 2020 5. REVENUE AND SEGMENT INFORMATION The Group is currently organised into three revenue streams, including Intermediate products, Bulk medicine and Finished products. (i) Disaggregation of revenue from contracts with customers For the year ended 31 December 2020 Intermediate Bulk Finished products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products – 6-APA 1,092,941 – – 1,092,941 – 1,092,941 – Antibiotics products – 3,609,573 2,091,597 5,701,170 – 5,701,170 – Insulin Products – – 1,165,605 1,165,605 – 1,165,605 – Others 336,749 11,147 464,876 812,772 – 812,772 Revenue from contracts with customers 1,429,690 3,620,720 3,722,078 8,772,488 – 8,772,488 Inter-segment sales 1,397,230 592,085 – 1,989,315 (1,989,315) – Segment revenue 2,826,920 4,212,805 3,722,078 10,761,803 (1,989,315) 8,772,488